- Many
cannabis companies have struggled with declining investor interest amid
product delivery shortfalls and adverse revenue reports
- The
distribution obstacles have exacerbated company concerns by creating
choking points for inventory, which can quickly lose potency in storage
- Lexaria
Bioscience’s trademarked DehydraTECH powder-creating technology helps
preserve cannabinoid effectiveness and extend storage potential 2 to 3
years
- The
DehydraTECH platform also provides a key benefit in making cannabinoids,
nicotine, NSAIDs and other drug products bioavailable as rapidly as
inhaled products
- An
alternative to inhaled smokes and vapes could provide health and wellness
benefits to consumers by eliminating harm to users’ lungs
- Lexaria’s
licensing strategy also enables other companies to utilize DehydraTECH’s
IP in their products
As the cannabis industry works to weather 2019’s adverse
profit and productivity reports (http://ibn.fm/niYkO), consumption drug platform
innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is
helping to ensure that product inventories can remain potent and perform at
their potential despite a natural tendency for cannabinoids to deteriorate with
time.
Public market investors have been short-term allies in a
fledgling industry seeking long-term commitment, in large part because of
initial sky-high expectations for profits from cannabis-related industries and
regulatory hurdles from government oversight of a once-illegal product that
have kept the brakes on runaway commerce. As a result, many companies have
built up outsized debt-revenue ratios (http://ibn.fm/G29Ig).
Added to those concerns, a European study determined that
the potency of tetrahydrocannabinol (THC) and cannabidiol (CBD) tends to
degrade over time – THC by 20 percent per year while in storage and CBD by 10
percent (http://ibn.fm/3Dj6d),
ensuring a need for producers to get their products to market in a timely
fashion. Additionally, a study of storage mediums used for THC found that
certain types of packaging can contribute to the degradation of the extract’s
potency (http://ibn.fm/w0INv).
The adverse factors have combined to create a potential
source of caution among consumers as some companies have had to report
multi-million-dollar losses due to “congested inventory channels” resulting
from production that has exceeded sales (http://ibn.fm/gbogP).
Lexaria’s product-stabilizing DehydraTECH(TM) oral drug
delivery IP turns cannabis and hemp oils into powders that preserve the
cannabinoid extracts in the products while mitigating microbiological growth to
help the products last longer on retail shelves – the company reports (http://ibn.fm/KEyQ4) that products
can be stored for two to three years and experience “reduced loss of
cannabinoids compared to current industry practices.”
DehydraTECH’s primary benefit is that it enables swallowed
drug substances to deliver their intended effects as rapidly and effectively as
inhaled products such as smokes or vapes. Many consumers continue to prefer
inhaling products containing nicotine-rich tobacco or cannabis-based marijuana
and CBD, acknowledging that they get a quicker, better response than if they
try to use other medicinal/wellness delivery methods.
The dangers of inhaling drug substances into the lungs have
been established over decades, with recent concerns about vape ingredients
adding new fuel to the fire (http://ibn.fm/ncC40).
Lexaria is committed to combatting the deleterious effects of drug inhalation
by making swallowed drug products more rapidly bioavailable in the bloodstream,
and thereby as attractive as inhaled products if not more so.
In addition to the DehydraTECH products Lexaria markets, the
company also licenses its technology to other companies for them to use in all
of their edible and topical cannabis and/or hemp extract processing needs.
Lexaria is able to process 250,000 servings of CBD at 10 mg each per day
currently for distribution across the country.
Although CBD-based wellness products continue to remain
under scrutiny by the federal government, many states have legalized topical
and edible uses. A recent licensing agreement between Lexaria and the smokeless
Cannadips CBD brand is drawing on DehydraTECH’s IP for a product chain
available nationally through Circle K convenience outlets, in about 5,000
stores throughout the United States.
For more information, visit the company’s website at www.LexariaBioscience.com
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
